

Patent Selections

The patents annotated in this section have been selected from various patent databases. These recent patents are relevant to the articles published in this journal issue, categorized by therapeutic areas/agent/targets and therapeutic agents related to CNS drug discovery.

PROTEIN ARRAY

1. Ferrani-Kile, K. Methods and compositions for obtaining and using biologically active multi-protein complexes. **US8470745 (2013)**.
2. Lüking, A., Kowald, A., Höpner, A., Scheer, C., Fiegl, H., Daxenbichler, G. Marker sequences for breast cancer and the use thereof. **WO2013093115A3 (2013)**.
3. Lüking, A., Kowald, A., Höpner, A., Schulz-Knappe, P., Scheer, C., Fiegl, H., Daxenbichler, G. method for identifying marker sequences for gynaecological malignant tumours. **WO2013087929A3 (2013)**.
4. Han, M. Method for the surface expression of a target protein using YIAT protein of E. Coli. **WO2013100217A1 (2013)**.
5. Lüking, A., Kowald, A., Höpner, A., Scheer, C., Fiegl, H., Daxenbichler, G. Marker sequences for breast cancer and the use thereof. **WO2013093115A2 (2013)**.
6. Lindsay, S., Labaer, J. Method and apparatus for measuring phosphorylation kinetics on large arrays. **WO2013090364A1 (2013)**.
7. Lüking, A., Kowald, A., Höpner, A., Schulz-Knappe, P., Scheer, C., Fiegl, H., Daxenbichler, G. Method for identifying marker sequences for gynaecological malignant tumours. **WO2013087929A2 (2013)**.
8. Han, M.J. Method for surface expressing of target protein using E. Coli YIAT protein. **KR2013075318A (2013)**.
9. Lützner, F. Zubereitung und Verfahren zum Nachweis von Mycobacterium avium ssp paratuberculosis (MAP). **DE12100396A1 (2013)**.
10. Jacobson, J., Hudson, M., Chu, L.L. Protein arrays and methods of using and making the same. **EP2637780A1 (2013)**.
11. He, W.W., Ma, D., Shu, Y., Sun, Z. Protein arrays and uses thereof. **KR2013000369A (2013)**.
12. Han, M.J. Method for surface expressing of target protein using E. Coli YIAT protein. **KR2013075318A (2013)**.

INFLAMMATION

1. Serhan, C.N., Clish, C.B. Aspirin-triggered lipid mediators. **US8349896 (2013)**.
2. Baylink, D.J., Lau, K.W., Qin, X. Agents and method for treating inflammation-related conditions and diseases. **WO2013123088A1 (2013)**.

3. Cohen, E.S., Minter, R.R., Harrison, P.R., Sleeman, M.A., Nash, A.D., Fabri, L.J. Antibody molecule for human GM-CSF receptor alpha. **US8506960 (2013)**.
4. Plat, J., Sverdlov, R., Mensink, R.P., Bieghs, V. Phytostanols for the prevention or treatment of Hepatic inflammation. **WO2013081462A1 (2013)**.
5. Edwards, J.P., Kindrachuk, D.E. Mapes, C.M., Pippel, D.J., Venable, J.D. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H₄ receptor. **US8343989 (2013)**.
6. El-Gewely, M.R. Antibacterial treatment of osteoarthritis. **US8349816 (2013)**.
7. Cho, J.Y., Yang, W.S., Hong, S.Y., Kim, T. W. Pharmaceutical compositions comprising methanol extract of Archidendron Clypearia, and using the same. **KR2013076975A (2013)**.
8. Tang, M. Anti-inflammation tea and preparation method thereof. **CN103156015A (2013)**.
9. Toshihisa, K., Kohn, K.I. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation. **WO2013103826A1 (2013)**.
10. Portillo, S.E., Videla, C.S. Compositions comprising tramadol and celecoxib in the treatment of pain. **US8569271 (2013)**.
11. Beswick, P.J., Campbell, A., Cridland, A.P., Gleave, R.J., Heer, J.P., Nicholson, N.H., Page, L.W., Vile, S. Piperazine derivatives used as CAV2.2 calcium channel modulators. **US8530478 (2013)**.
12. Doshan, H.D. Perez, J. Synthesis of R-N-methylnaltrexone. **US8343992 (2013)**.

(TRANSCRANIAL DOPPLER)

1. Mou, X., Chen, R., Xiang, L., Liu, T., Ye, D. System and method of brain blood flow measurement. **CN103169503A (2013)**.
2. Tyler, W.J., Mourad, P., Wetmore, D.Z. Device and methods for targeting of transcranial ultrasound neuromodulation by automated transcranial doppler imaging. **WO2013152035A1 (2013)**.
3. Kim, H.J. Transcranial doppler device and method thereof. **KR2013061849A (2013)**.

NEUROTOXICITY

1. Mahrhold, S., Bigalke, J., Wilhelm, R., Andreas, B.T. Botulinum neurotoxin a protein receptor and uses thereof. **US8476024 (2013)**.

2. DiMauro, T.M. Methylated curcumin-resveratrol hybrid molecules for treating cancer. **US8350093 (2013)**.
3. Jeromin, A., Glushakova, O., Wang, K.K., Zhang, Z., Hayes, R.L. Markers and assays for detection of neurotoxicity. **CN102918397A (2013)**.
4. Mullan, M.D., Pari, D., Ajvi, R.A. Method of reducing amyloid deposition, amyloid neurotoxicity and microgliosis by (-)-ENANTIOMER nilvadipine. **RU2490014C2 (2013)**.
5. Wulff, H., Jin, L.W., Maezawa, I. Reduction of microglia-mediated neurotoxicity by KV1.3 inhibition. **WO2012170917A3 (2013)**.
6. Rummel, A., Weil, T., Gutcaits, A. Carrier for targeting nerve cells. **US8481040 (2013)**.
7. Duggan, M. E. Azaquinolinone derivatives and uses thereof. **US8343996 (2013)**.
8. Xu, Y., LI, L., Zhang, L. Application of CART (Cocaine Amphetamine Regulated Transcript) in preparing medicaments for treating alzheimers diseases. **CN101874895B (2013)**.
9. Muzumdar, R., Casper, D., Lekhraj, R. Humanin protection of dopaminergic neurons. **WO2013066374A3 (2013)**.
10. Kharul, R., Bhuniya, D., Mookhtiar, K.A., Singh, U., Hazare, A., Patil, S., Datrange, L., Thakkar, M. Amide compounds, compositions and applications thereof. **WO2013042139A1 (2013)**.
11. Hao, J., Wang, L. Ceftriaxone sodium pharmaceutical composition and preparation method thereof. **CN103142615A (2013)**.
12. Schulte, J., Sepp, K.J., Littleton, J. Chemical and RNAI suppressors of neurotoxicity in huntington's disease. **EP2646045A1 (2013)**.
2. Ku, Y.H., Yang, Y.J., Park, Y.M., Song, S.Y., Han, Y.D., Kim, M.S., Yoon, H.C. Electrode for measuring glycoprotein and preparation method thereof. **JP2013024870A2 (2013)**.
3. Ku, Y.H., Yang, Y.J., Park, Y.M., Song, S.Y., Han, Y.D., Kim, M.S., Yoon, H.C. Electrode for measuring glycoprotein and preparation method thereof. **EP2546653A1 (2013)**.
4. Rattenholl, A., Grossmann, A., Schwarz, E., Rudolph, R. Method for obtaining active pro-NGF and beta-NGF. **US8501439 (2013)**.
5. Suarez, G. Immobilisation of biological molecules. **US8497106 (2013)**.
6. Schmaus, G., Lange, S., Ohrmann, R., Issleib, M. Polyethylene glycol esters and cosmetic and/or dermatological preparations. **US8476318 (2013)**.
7. Ohrmann, R., Issleib, M., Endlein, E., Schröder, B. O/W-emulsifiers, O/W-emulsions and methods of manufacture thereof. **US8454941 (2013)**.

TRANSGLUTAMINASES

1. Pan, L., Wang, K., Yang, H. Method for producing microbial transglutaminase by use of pro-transglutaminase. **CN102952815A (2013)**.
2. Lee, A. Composition for preventing, treating or alleviating atopic dermatitis comprising immunosuppressant and transglutaminase 2 inhibitor. **WO2013077617A1 (2013)**.
3. Okada, M., Kurono, Y., Amano, H., Yamaguchi, S. Stabilized transglutaminase and process for production thereof. **CN101945995B (2013)**.
4. Ha, K.S., Kwon, M.H. Methods for simultaneously determining blood coagulation factor xiii and Transglutaminase 2 activities. **KR2013061838A (2013)**.

CYSTAMINE

1. Dohil, R., Phillips, S.A. Cysteamine and/or cystamine for treating ischemic injury. **WO2013078335A1 (2013)**.